News Conference News ACC 2020 Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH Yael L. Maxwell April 06, 2020
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News ACC 2020 Evinacumab Cuts LDL Cholesterol in Homozygous FH Yael L. Maxwell April 01, 2020
Presentation ACC 2020 Evinacumab in Patients with Homozygous Familial Hypercholesterolemia Presenter: Frederick Raal March 30, 2020
Presentation ACC 2020 EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial Presenter: Deepak L. Bhatt March 30, 2020
Presentation ACC 2020 Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH) Presenter: Dirk J. Blom March 30, 2020
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
Presentation ACC 2020 VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel Presenter: William Hiatt March 29, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
News Conference News ACC 2020 Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity Yael L. Maxwell March 19, 2020